Neurological graft-versus-host disease with MOG antibody positivity after allogeneic stem cell transplantation: a case report

This case illustrates low-titer post-HSCT MOG seropositivity detected only by a live cell-based assay in a patient who fulfilled diagnostic criteria for CNS-GVHD. Live cell-based MOG testing may be considered in selected HSCT recipients with unexplained or atypical neuroinflammatory syndromes despite negative conventional assays, with results interpreted cautiously as hypothesis-generating for individualized immunosuppressive management.